These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30379088)

  • 1. Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review.
    Raouf S; Bertelli G; Ograbek A; Field P; Tran I
    Future Oncol; 2019 Feb; 15(5):543-561. PubMed ID: 30379088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse effects of bevacizumab in metastatic colorectal cancer : a case report and literature review.
    Willems E; Gerne L; George C; D'Hondt M
    Acta Gastroenterol Belg; 2019; 82(2):322-325. PubMed ID: 31314196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab Efficacy and Recurrence Pattern of Persistent and Metastatic Cervical Cancer.
    Lee N; Kim SI; Lee M; Kim HS; Kim JW; Park NH; Song YS
    In Vivo; 2019; 33(3):863-868. PubMed ID: 31028209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
    Haunschild CE; Tewari KS
    Future Oncol; 2020 Mar; 16(7):225-246. PubMed ID: 31746224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis.
    Cao D; Zheng Y; Xu H; Ge W; Xu X
    Sci Rep; 2019 Dec; 9(1):20326. PubMed ID: 31889159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study.
    Ranieri G; Ferrari C; Di Palo A; Marech I; Porcelli M; Falagario G; Ritrovato F; Ramunni L; Fanelli M; Rubini G; Gadaleta CD
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28684680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab in Cervical Cancer: 5 Years After.
    Pfaendler KS; Liu MC; Tewari KS
    Cancer J; 2018; 24(4):187-192. PubMed ID: 30119082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. bevacizumab (Avastin°) in persistent, recurrent or metastatic cervical cancer: Prolongs survival by a few months, but highly toxic.
    Prescrire Int; 2016 Oct; 25(175):233. PubMed ID: 30645824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis.
    Baraniskin A; Buchberger B; Pox C; Graeven U; Holch JW; Schmiegel W; Heinemann V
    Eur J Cancer; 2019 Jan; 106():37-44. PubMed ID: 30476731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
    Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons.
    Sini V; Cassano A; Corsi D; De Laurentiis M; Gamucci T; Mauri M; Naso G; Roselli M; Ruggeri EM; Tonini G; Vici P; Zampa G; Marchetti P
    Tumori; 2016 Oct; 102(5):472-480. PubMed ID: 27647231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
    Wu YS; Shui L; Shen D; Chen X
    Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
    JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
    Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
    Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
    Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
    Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F
    World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability and Efficacy of Bevacizumab Monotherapy in Older Patients With Recurrent Ovarian Cancer.
    Shintani D; Yoshida H; Yabuno A; Fujiwara K
    In Vivo; 2020; 34(3):1451-1457. PubMed ID: 32354945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women.
    Su J; Lai J; Yang R; Xu B; Zhu Y; Zhao M; Yang C; Liang G
    BMC Gastroenterol; 2019 Jan; 19(1):17. PubMed ID: 30683047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer.
    Kapelakis I; Toutouzas K; Drakopoulou M; Michelongona A; Zagouri F; Mpamias A; Pliatsika P; Dimopoulos MA; Stefanadis C; Tousoulis D
    Hellenic J Cardiol; 2017; 58(3):215-219. PubMed ID: 28258825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.